Why the study?
To investigate whether elevated AGE-albumin from activated macrophages contributes to ischemia-induced cardiomyocyte death and to develop therapeutic strategies targeting the AGE-RAGE system in acute myocardial infarction.
Do sRAGE-secreting MSCs improve therapeutic effects against AMI pathogenesis in a rat model of myocardial infarction?
Do sRAGE-secreting MSCs improve therapeutic effects against AMI pathogenesis in a rat model of myocardial infarction?
p-value: p=<0.001
sRAGE-secreting MSCs generated via CRISPR/Cas9 demonstrate protective effects against AMI pathogenesis in a rat model, suggesting a potential therapeutic strategy targeting the AGE-RAGE system.
Hypothesis-generating for sRAGE-engineered MSCs in rodent AMI; prospective human trials required before any clinical consideration.
Acute myocardial infarction (AMI) is one of the major leading causes of death in humans globally. Recently, increased levels of recruited macrophages and AGE-albumin were observed in the hearts of humans and animals with acute myocardial infarction. Thus, the purposes of this study were to investigate whether the elevated levels of AGE-albumin from activated macrophage cells are implicated in ischemia-induced cardiomyocyte death and to develop therapeutic strategies for AMI based on its underlying molecular mechanisms with respect to AGEs. The present study demonstrated that activated macrophages and AGE-albumin were observed in heart tissues obtained from humans and rats with AMI incidences. In the cellular model of AMI, it was found that increased expression of AGE-albumin was shown to be co-localized with macrophages, and the presence of AGE-albumin led to increased expression of RAGE through the mitogen-activated protein kinase pathway. After revealing cardiomyocyte apoptosis induced by toxicity of the AGE-RAGE system, sRAGE-secreting MSCs were generated using the CRISPR/Cas9 platform to investigate the therapeutic effects of sRAGE-MSCs in an AMI rat model. Gene-edited sRAGE-MSCs showed greater therapeutic effects against AMI pathogenesis in rat models compared to mock MSCs, and promising results of the functional improvement of stem cells could result in significant improvements in the clinical management of cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Bayarsaikhan et al. (2022) studied Acute myocardial infarction. sRAGE-secreting MSCs vs. PBS or GFP-MSCs was evaluated on Infarct size and fibrosis (p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: